| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Mantle-Cell | 44 | 2022 | 719 | 10.330 |
Why?
|
| Multiple Myeloma | 61 | 2015 | 2152 | 4.610 |
Why?
|
| Pyrazines | 24 | 2019 | 495 | 3.410 |
Why?
|
| Thalidomide | 27 | 2017 | 570 | 2.960 |
Why?
|
| Boronic Acids | 22 | 2014 | 363 | 2.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2022 | 15874 | 2.120 |
Why?
|
| Pyrazoles | 8 | 2019 | 1479 | 1.870 |
Why?
|
| Oligopeptides | 9 | 2013 | 425 | 1.560 |
Why?
|
| Pyrimidines | 9 | 2019 | 3538 | 1.480 |
Why?
|
| Antineoplastic Agents | 36 | 2019 | 14288 | 1.440 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2019 | 4768 | 1.280 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2015 | 1759 | 1.270 |
Why?
|
| Dexamethasone | 20 | 2013 | 1450 | 1.260 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 9 | 2018 | 1667 | 1.170 |
Why?
|
| Bortezomib | 22 | 2014 | 544 | 1.160 |
Why?
|
| Adenine | 10 | 2022 | 639 | 1.100 |
Why?
|
| Rituximab | 18 | 2022 | 1534 | 1.020 |
Why?
|
| Drug Resistance, Neoplasm | 20 | 2019 | 5183 | 0.970 |
Why?
|
| Apoptosis | 23 | 2019 | 7601 | 0.970 |
Why?
|
| Piperidines | 10 | 2022 | 1053 | 0.930 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 15 | 2014 | 869 | 0.900 |
Why?
|
| Benzamides | 2 | 2019 | 1834 | 0.890 |
Why?
|
| Spiro Compounds | 4 | 2011 | 59 | 0.850 |
Why?
|
| Recurrence | 18 | 2017 | 4784 | 0.820 |
Why?
|
| Lymphopenia | 2 | 2022 | 199 | 0.800 |
Why?
|
| Salvage Therapy | 8 | 2015 | 2059 | 0.780 |
Why?
|
| Mice, SCID | 16 | 2014 | 1865 | 0.770 |
Why?
|
| Cell Proliferation | 17 | 2019 | 7241 | 0.750 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2013 | 590 | 0.740 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2015 | 393 | 0.730 |
Why?
|
| Lymphoma, B-Cell | 7 | 2015 | 897 | 0.700 |
Why?
|
| Neutropenia | 6 | 2015 | 965 | 0.660 |
Why?
|
| Aged | 62 | 2020 | 70367 | 0.660 |
Why?
|
| Treatment Outcome | 42 | 2022 | 33028 | 0.660 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 847 | 0.650 |
Why?
|
| Middle Aged | 65 | 2022 | 86544 | 0.620 |
Why?
|
| Humans | 131 | 2022 | 262248 | 0.620 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 406 | 0.600 |
Why?
|
| Aged, 80 and over | 37 | 2019 | 29996 | 0.600 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2011 | 273 | 0.590 |
Why?
|
| Melphalan | 12 | 2015 | 834 | 0.590 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2019 | 10067 | 0.560 |
Why?
|
| Molecular Targeted Therapy | 4 | 2015 | 2334 | 0.540 |
Why?
|
| Drug Substitution | 2 | 2015 | 87 | 0.530 |
Why?
|
| Male | 69 | 2020 | 123338 | 0.520 |
Why?
|
| Maintenance Chemotherapy | 2 | 2015 | 202 | 0.520 |
Why?
|
| Antibodies, Monoclonal | 16 | 2013 | 4386 | 0.510 |
Why?
|
| B-Lymphocytes | 3 | 2019 | 1307 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 15 | 2013 | 6607 | 0.500 |
Why?
|
| Disease-Free Survival | 22 | 2015 | 10021 | 0.500 |
Why?
|
| Cyclophosphamide | 13 | 2022 | 3080 | 0.490 |
Why?
|
| Electroacupuncture | 1 | 2014 | 35 | 0.480 |
Why?
|
| Leukemia, B-Cell | 1 | 2015 | 116 | 0.480 |
Why?
|
| Drug Synergism | 10 | 2013 | 1316 | 0.470 |
Why?
|
| Disease Progression | 12 | 2019 | 6693 | 0.470 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2014 | 1041 | 0.470 |
Why?
|
| Protease Inhibitors | 3 | 2012 | 210 | 0.470 |
Why?
|
| Lymphoma, Follicular | 4 | 2014 | 591 | 0.460 |
Why?
|
| Adult | 44 | 2022 | 78179 | 0.450 |
Why?
|
| Proteasome Inhibitors | 2 | 2013 | 230 | 0.440 |
Why?
|
| Doxorubicin | 12 | 2022 | 3005 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2015 | 6223 | 0.430 |
Why?
|
| Cell Line, Tumor | 28 | 2018 | 14561 | 0.430 |
Why?
|
| Female | 66 | 2019 | 142293 | 0.430 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2013 | 566 | 0.420 |
Why?
|
| Drug Discovery | 1 | 2015 | 326 | 0.420 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2018 | 923 | 0.410 |
Why?
|
| Vincristine | 10 | 2022 | 1508 | 0.400 |
Why?
|
| beta 2-Microglobulin | 5 | 2011 | 184 | 0.400 |
Why?
|
| Remission Induction | 9 | 2013 | 3584 | 0.390 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 3233 | 0.370 |
Why?
|
| Blotting, Western | 13 | 2014 | 3529 | 0.370 |
Why?
|
| Diarrhea | 4 | 2015 | 689 | 0.370 |
Why?
|
| Immunosuppressive Agents | 3 | 2015 | 1416 | 0.370 |
Why?
|
| Transplantation, Autologous | 12 | 2013 | 1925 | 0.360 |
Why?
|
| Sirolimus | 1 | 2014 | 818 | 0.350 |
Why?
|
| Fatigue | 5 | 2015 | 1239 | 0.340 |
Why?
|
| Methotrexate | 5 | 2022 | 1002 | 0.340 |
Why?
|
| Survival Analysis | 10 | 2017 | 9195 | 0.340 |
Why?
|
| Sulfonamides | 1 | 2018 | 1826 | 0.330 |
Why?
|
| Animals | 34 | 2018 | 59489 | 0.330 |
Why?
|
| Signal Transduction | 11 | 2019 | 11972 | 0.330 |
Why?
|
| Acupuncture Therapy | 1 | 2009 | 89 | 0.320 |
Why?
|
| Hematologic Diseases | 4 | 2014 | 241 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 4945 | 0.300 |
Why?
|
| Drug Administration Schedule | 8 | 2015 | 3482 | 0.300 |
Why?
|
| Cyclin D1 | 2 | 2010 | 577 | 0.300 |
Why?
|
| Time Factors | 10 | 2019 | 12984 | 0.300 |
Why?
|
| Antigens, CD20 | 1 | 2008 | 206 | 0.300 |
Why?
|
| Blood Viscosity | 1 | 2007 | 23 | 0.300 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2009 | 749 | 0.290 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2013 | 1247 | 0.290 |
Why?
|
| Immunotherapy | 3 | 2009 | 3347 | 0.280 |
Why?
|
| Mice | 27 | 2018 | 34393 | 0.280 |
Why?
|
| Oncology Nursing | 1 | 2007 | 51 | 0.280 |
Why?
|
| Administration, Oral | 4 | 2015 | 1554 | 0.280 |
Why?
|
| Cytarabine | 5 | 2022 | 1976 | 0.270 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 120 | 0.260 |
Why?
|
| Myeloablative Agonists | 4 | 2015 | 389 | 0.260 |
Why?
|
| Survival Rate | 13 | 2015 | 12239 | 0.260 |
Why?
|
| Transplantation Conditioning | 7 | 2015 | 2286 | 0.260 |
Why?
|
| Mitochondria | 2 | 2013 | 1281 | 0.250 |
Why?
|
| In Vitro Techniques | 4 | 2011 | 1614 | 0.240 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 14913 | 0.230 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2010 | 219 | 0.220 |
Why?
|
| Deoxycytidine | 3 | 2013 | 1360 | 0.220 |
Why?
|
| Amyloidosis | 2 | 2015 | 175 | 0.220 |
Why?
|
| Stem Cell Transplantation | 4 | 2015 | 1367 | 0.210 |
Why?
|
| Composite Lymphoma | 2 | 2012 | 15 | 0.210 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2022 | 108 | 0.210 |
Why?
|
| SEER Program | 3 | 2011 | 1000 | 0.210 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7218 | 0.200 |
Why?
|
| Mice, Inbred NOD | 6 | 2014 | 904 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 1294 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2018 | 3818 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2015 | 2633 | 0.180 |
Why?
|
| Prodrugs | 1 | 2001 | 218 | 0.180 |
Why?
|
| Immunophenotyping | 5 | 2014 | 1684 | 0.170 |
Why?
|
| Reactive Oxygen Species | 3 | 2013 | 980 | 0.170 |
Why?
|
| Interleukin-6 | 4 | 2012 | 1031 | 0.170 |
Why?
|
| Testicular Neoplasms | 1 | 2002 | 528 | 0.160 |
Why?
|
| Age Distribution | 2 | 2011 | 703 | 0.160 |
Why?
|
| Retrospective Studies | 17 | 2015 | 38011 | 0.160 |
Why?
|
| Oncogene Protein v-akt | 1 | 2018 | 102 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1435 | 0.150 |
Why?
|
| Retreatment | 2 | 2015 | 453 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2011 | 706 | 0.150 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 669 | 0.150 |
Why?
|
| Pain | 3 | 2014 | 1667 | 0.150 |
Why?
|
| Combined Modality Therapy | 5 | 2014 | 8885 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 5009 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2009 | 622 | 0.140 |
Why?
|
| Immunologic Factors | 2 | 2013 | 653 | 0.140 |
Why?
|
| NF-kappa B | 3 | 2012 | 1551 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2018 | 1684 | 0.140 |
Why?
|
| Killer Cells, Natural | 2 | 2013 | 907 | 0.140 |
Why?
|
| Epistaxis | 1 | 2015 | 30 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2012 | 1487 | 0.130 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 130 | 0.130 |
Why?
|
| Macrophages | 2 | 2014 | 1313 | 0.130 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2014 | 109 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2015 | 159 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 1439 | 0.120 |
Why?
|
| Lymphoma | 1 | 2002 | 1471 | 0.120 |
Why?
|
| Risk | 2 | 2015 | 1974 | 0.120 |
Why?
|
| Macrophage Activation | 1 | 2014 | 146 | 0.120 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 300 | 0.120 |
Why?
|
| Biological Factors | 1 | 2013 | 46 | 0.120 |
Why?
|
| Neoplasm Staging | 8 | 2014 | 13669 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2015 | 1392 | 0.120 |
Why?
|
| Portraits as Topic | 1 | 2013 | 6 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2013 | 3550 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 1668 | 0.110 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2013 | 57 | 0.110 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 93 | 0.110 |
Why?
|
| Nausea | 1 | 2015 | 525 | 0.110 |
Why?
|
| Plasma Cells | 2 | 2011 | 194 | 0.110 |
Why?
|
| Cancer Vaccines | 2 | 2009 | 699 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 8 | 2013 | 5378 | 0.110 |
Why?
|
| Acrylates | 1 | 2012 | 30 | 0.110 |
Why?
|
| Verapamil | 1 | 2012 | 79 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 284 | 0.110 |
Why?
|
| DNA Damage | 2 | 2018 | 1947 | 0.110 |
Why?
|
| Monoterpenes | 1 | 2012 | 10 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 249 | 0.100 |
Why?
|
| Tumor Microenvironment | 2 | 2013 | 2860 | 0.100 |
Why?
|
| Registries | 2 | 2011 | 2188 | 0.100 |
Why?
|
| Comorbidity | 4 | 2014 | 2397 | 0.100 |
Why?
|
| Dyspnea | 1 | 2015 | 417 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2009 | 142 | 0.100 |
Why?
|
| Ascorbic Acid | 2 | 2011 | 130 | 0.100 |
Why?
|
| Phosphorylation | 5 | 2013 | 4809 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2014 | 5339 | 0.100 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2011 | 19 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 488 | 0.100 |
Why?
|
| Oxides | 2 | 2011 | 211 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 246 | 0.100 |
Why?
|
| Incidence | 3 | 2012 | 5713 | 0.100 |
Why?
|
| Arsenicals | 2 | 2011 | 201 | 0.100 |
Why?
|
| Urate Oxidase | 1 | 2011 | 35 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 1493 | 0.100 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2011 | 29 | 0.100 |
Why?
|
| Everolimus | 1 | 2014 | 415 | 0.100 |
Why?
|
| Osteoblasts | 1 | 2014 | 362 | 0.100 |
Why?
|
| Transglutaminases | 1 | 2012 | 101 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 4323 | 0.100 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2011 | 34 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2011 | 68 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2014 | 2302 | 0.100 |
Why?
|
| Karyopherins | 1 | 2012 | 135 | 0.100 |
Why?
|
| Age Factors | 5 | 2014 | 5384 | 0.100 |
Why?
|
| Membrane Microdomains | 2 | 2011 | 81 | 0.100 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2010 | 10 | 0.100 |
Why?
|
| Protein Transport | 1 | 2013 | 734 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 222 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2013 | 673 | 0.100 |
Why?
|
| Cyclin D2 | 1 | 2010 | 40 | 0.100 |
Why?
|
| Cell Survival | 6 | 2014 | 3042 | 0.100 |
Why?
|
| Gout Suppressants | 1 | 2011 | 70 | 0.090 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 204 | 0.090 |
Why?
|
| Proteomics | 1 | 2018 | 1386 | 0.090 |
Why?
|
| Guanidines | 1 | 2010 | 60 | 0.090 |
Why?
|
| Jaundice, Obstructive | 1 | 2010 | 16 | 0.090 |
Why?
|
| Fetal Blood | 1 | 2013 | 480 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 419 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 347 | 0.090 |
Why?
|
| Interleukin-2 | 3 | 2013 | 842 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2012 | 321 | 0.090 |
Why?
|
| Filgrastim | 2 | 2009 | 192 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 8882 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2011 | 234 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2012 | 301 | 0.090 |
Why?
|
| Metformin | 1 | 2014 | 378 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2010 | 447 | 0.090 |
Why?
|
| United States | 4 | 2012 | 15574 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2014 | 981 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 346 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 166 | 0.090 |
Why?
|
| Diphtheria Toxin | 2 | 2007 | 82 | 0.090 |
Why?
|
| Models, Biological | 1 | 2019 | 3242 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 586 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2010 | 424 | 0.090 |
Why?
|
| Phenols | 1 | 2010 | 107 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 253 | 0.090 |
Why?
|
| Cell Cycle | 3 | 2010 | 2085 | 0.090 |
Why?
|
| Annexin A2 | 1 | 2009 | 15 | 0.090 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2009 | 26 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2012 | 2393 | 0.090 |
Why?
|
| Blood Cells | 1 | 2009 | 128 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 207 | 0.090 |
Why?
|
| Chromosome Aberrations | 2 | 2014 | 1957 | 0.090 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2009 | 37 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 587 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 1077 | 0.080 |
Why?
|
| Major Histocompatibility Complex | 1 | 2009 | 94 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 1290 | 0.080 |
Why?
|
| Epitopes | 1 | 2011 | 682 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2010 | 397 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2015 | 738 | 0.080 |
Why?
|
| Insulin | 1 | 2014 | 1446 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 723 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2012 | 584 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2009 | 240 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2009 | 1148 | 0.080 |
Why?
|
| Triazoles | 1 | 2012 | 618 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 621 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2011 | 628 | 0.080 |
Why?
|
| Young Adult | 5 | 2014 | 21494 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 506 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2013 | 1618 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 1 | 2008 | 140 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 311 | 0.080 |
Why?
|
| Pneumonia | 1 | 2014 | 754 | 0.080 |
Why?
|
| Dendritic Cells | 3 | 2011 | 1088 | 0.080 |
Why?
|
| Caspases | 2 | 2007 | 662 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2009 | 265 | 0.080 |
Why?
|
| Placebos | 1 | 2008 | 442 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2013 | 5598 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 2 | 2012 | 1122 | 0.070 |
Why?
|
| Bone Transplantation | 1 | 2008 | 138 | 0.070 |
Why?
|
| Receptors, IgG | 1 | 2007 | 101 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1350 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 600 | 0.070 |
Why?
|
| Nursing Assessment | 1 | 2007 | 42 | 0.070 |
Why?
|
| Confusion | 1 | 2007 | 31 | 0.070 |
Why?
|
| Social Class | 1 | 2008 | 311 | 0.070 |
Why?
|
| Information Services | 1 | 2007 | 50 | 0.070 |
Why?
|
| HLA-A Antigens | 1 | 2007 | 105 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2014 | 11571 | 0.070 |
Why?
|
| Nurse's Role | 1 | 2007 | 42 | 0.070 |
Why?
|
| beta Catenin | 1 | 2010 | 687 | 0.070 |
Why?
|
| Prednisone | 3 | 2014 | 983 | 0.070 |
Why?
|
| Bone Marrow Examination | 1 | 2007 | 152 | 0.070 |
Why?
|
| Imidazoles | 1 | 2012 | 1003 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2009 | 1382 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 321 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7566 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 1016 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 327 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2014 | 2297 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 603 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 745 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 323 | 0.070 |
Why?
|
| Indoles | 1 | 2011 | 1011 | 0.070 |
Why?
|
| Vinblastine | 1 | 2006 | 453 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2008 | 291 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 719 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2006 | 140 | 0.070 |
Why?
|
| Antioxidants | 1 | 2008 | 511 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 499 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 2892 | 0.070 |
Why?
|
| Calcium | 1 | 2012 | 1545 | 0.060 |
Why?
|
| RNA | 1 | 2010 | 1010 | 0.060 |
Why?
|
| Bleomycin | 1 | 2006 | 467 | 0.060 |
Why?
|
| Peptides | 2 | 2011 | 1476 | 0.060 |
Why?
|
| Aorta | 1 | 2009 | 690 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4355 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 507 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2007 | 244 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 1516 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 1505 | 0.060 |
Why?
|
| Mutation | 2 | 2014 | 15167 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 2915 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2008 | 605 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 373 | 0.060 |
Why?
|
| Bone Marrow | 2 | 2009 | 2360 | 0.060 |
Why?
|
| Autografts | 2 | 2015 | 166 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 483 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2001 | 4838 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 1545 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 3755 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 526 | 0.060 |
Why?
|
| Texas | 1 | 2015 | 6308 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1359 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 645 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2007 | 637 | 0.060 |
Why?
|
| Prognosis | 8 | 2014 | 21737 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 1351 | 0.060 |
Why?
|
| Pain Management | 1 | 2009 | 670 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 2156 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1002 | 0.050 |
Why?
|
| Risk Factors | 3 | 2015 | 17622 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2012 | 9282 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2007 | 715 | 0.050 |
Why?
|
| Internet | 1 | 2007 | 715 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 5155 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 3632 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 758 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2010 | 5253 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2012 | 3022 | 0.050 |
Why?
|
| Liver | 1 | 2011 | 2904 | 0.050 |
Why?
|
| Colitis | 1 | 2004 | 340 | 0.050 |
Why?
|
| Biomarkers, Tumor | 3 | 2015 | 10348 | 0.050 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2014 | 278 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2007 | 899 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2006 | 635 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2004 | 15709 | 0.050 |
Why?
|
| Taxoids | 1 | 2004 | 970 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 2 | 2011 | 186 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 3891 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2011 | 342 | 0.050 |
Why?
|
| Capecitabine | 1 | 2001 | 388 | 0.050 |
Why?
|
| Genotype | 1 | 2008 | 4104 | 0.050 |
Why?
|
| K562 Cells | 2 | 2013 | 339 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 856 | 0.040 |
Why?
|
| Carcinoma, Embryonal | 1 | 1999 | 29 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2011 | 181 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2005 | 1557 | 0.040 |
Why?
|
| Fenretinide | 1 | 1999 | 96 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2012 | 1077 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 1165 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2014 | 2232 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 696 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 7545 | 0.040 |
Why?
|
| Antigens, CD19 | 2 | 2011 | 579 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 4787 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1999 | 365 | 0.040 |
Why?
|
| Graft Survival | 2 | 2012 | 1072 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2012 | 625 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2013 | 5672 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2011 | 591 | 0.040 |
Why?
|
| Translocation, Genetic | 2 | 2014 | 1244 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2001 | 1946 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2011 | 2062 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2013 | 12923 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 2420 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 3879 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 2215 | 0.030 |
Why?
|
| Transfection | 2 | 2010 | 2934 | 0.030 |
Why?
|
| Base Sequence | 2 | 2013 | 4886 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 1901 | 0.030 |
Why?
|
| Threonine | 1 | 2014 | 162 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 127 | 0.030 |
Why?
|
| Thiourea | 1 | 2013 | 18 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2013 | 15 | 0.030 |
Why?
|
| Cell Tracking | 1 | 2014 | 38 | 0.030 |
Why?
|
| Methionine | 1 | 2014 | 159 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2013 | 22 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2013 | 47 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 167 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 113 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 83 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 2014 | 120 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2013 | 83 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 286 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 2344 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2014 | 389 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2013 | 93 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2012 | 47 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2013 | 312 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 358 | 0.030 |
Why?
|
| Perilla | 1 | 2012 | 2 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2010 | 3127 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 734 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 4745 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 626 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 165 | 0.030 |
Why?
|
| Primary Graft Dysfunction | 1 | 2012 | 36 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 345 | 0.030 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2011 | 51 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2012 | 247 | 0.020 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 351 | 0.020 |
Why?
|
| Consolidation Chemotherapy | 1 | 2012 | 154 | 0.020 |
Why?
|
| Wnt3 Protein | 1 | 2010 | 17 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2007 | 2605 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 37 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 662 | 0.020 |
Why?
|
| MafB Transcription Factor | 1 | 2010 | 13 | 0.020 |
Why?
|
| Casein Kinase Ialpha | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2013 | 648 | 0.020 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2011 | 61 | 0.020 |
Why?
|
| Uric Acid | 1 | 2011 | 109 | 0.020 |
Why?
|
| Wnt3A Protein | 1 | 2010 | 29 | 0.020 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 72 | 0.020 |
Why?
|
| DNA Primers | 1 | 2013 | 1395 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2009 | 1596 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 598 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 438 | 0.020 |
Why?
|
| S Phase | 1 | 2011 | 281 | 0.020 |
Why?
|
| Tretinoin | 1 | 2013 | 622 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 288 | 0.020 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2010 | 38 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2010 | 163 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 1557 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1001 | 0.020 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 437 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 220 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 366 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 160 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 719 | 0.020 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2009 | 21 | 0.020 |
Why?
|
| Graft vs Host Disease | 2 | 2012 | 2734 | 0.020 |
Why?
|
| Topotecan | 1 | 2010 | 239 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2010 | 144 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2009 | 112 | 0.020 |
Why?
|
| Thromboplastin | 1 | 2009 | 34 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1221 | 0.020 |
Why?
|
| Quinazolines | 1 | 2014 | 924 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 1063 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 133 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2011 | 259 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 505 | 0.020 |
Why?
|
| E-Selectin | 1 | 2009 | 101 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 169 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 391 | 0.020 |
Why?
|
| Brain | 1 | 2002 | 4097 | 0.020 |
Why?
|
| Benzylamines | 1 | 2009 | 103 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2009 | 118 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 311 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2007 | 4126 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2009 | 220 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1034 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2009 | 152 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2009 | 119 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 559 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 346 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 610 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 640 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 692 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2010 | 773 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2013 | 1047 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 538 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2013 | 1129 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 873 | 0.020 |
Why?
|
| Hemagglutinins, Viral | 1 | 2006 | 45 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2007 | 157 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 786 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2011 | 790 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2006 | 86 | 0.020 |
Why?
|
| Phospholipase C gamma | 1 | 2006 | 54 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 848 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2009 | 485 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2007 | 159 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3438 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 3846 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2007 | 272 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2170 | 0.020 |
Why?
|
| Influenza B virus | 1 | 2006 | 127 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2504 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 809 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2006 | 298 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 465 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 591 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2006 | 189 | 0.020 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2006 | 152 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 260 | 0.020 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2005 | 24 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 2804 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 815 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 2325 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 1030 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 302 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 190 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 2078 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 460 | 0.020 |
Why?
|
| DNA Repair | 1 | 2013 | 1870 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2006 | 356 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 7717 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 875 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3563 | 0.020 |
Why?
|
| Piperazines | 1 | 2013 | 2098 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2013 | 1587 | 0.020 |
Why?
|
| Hypoalbuminemia | 1 | 2004 | 46 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 186 | 0.020 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2006 | 242 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 5124 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 1040 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 2004 | 170 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2004 | 170 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 34 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2006 | 437 | 0.010 |
Why?
|
| Stents | 1 | 2010 | 1100 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2006 | 479 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 6129 | 0.010 |
Why?
|
| RNA Interference | 1 | 2007 | 1411 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1379 | 0.010 |
Why?
|
| Medicare | 1 | 2007 | 898 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 1035 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1760 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 6900 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 4556 | 0.010 |
Why?
|
| Proteins | 1 | 2009 | 1953 | 0.010 |
Why?
|
| Vaccination | 1 | 2007 | 1125 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2004 | 517 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 1900 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 1317 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 661 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 2063 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2013 | 2955 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 1999 | 85 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 4903 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 6927 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 1998 | 0.010 |
Why?
|
| Cell Death | 1 | 1999 | 672 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 2207 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 31239 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 6932 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1999 | 4043 | 0.000 |
Why?
|